X4 Pharmaceuticals (XFOR) Operating Expenses (2017 - 2025)

X4 Pharmaceuticals' Operating Expenses history runs 9 years deep, the most recent figure standing at $25.9 million for Q4 2025.

• Quarterly Operating Expenses fell 29.7% year-over-year to $25.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $116.2 million (down 18.81% YoY) and the FY2025 annual result came in at $116.2 million, up 198.37% from the prior year.
• Operating Expenses was $25.9 million for Q4 2025 at X4 Pharmaceuticals, down from $28.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $37.3 million in Q1 2024 and bottomed at $17.9 million in Q1 2021.
• A 5-year average of $27.0 million and a median of $26.6 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2021 — Operating Expenses jumped 64.57% — and 2025, when it fell 29.7%.
• X4 Pharmaceuticals' Operating Expenses stood at $29.1 million in 2021, then slipped by 11.97% to $25.6 million in 2022, then fell by 1.48% to $25.2 million in 2023, then jumped by 46.22% to $36.8 million in 2024, then retreated by 29.7% to $25.9 million in 2025.
• Business Quant data shows XFOR's Operating Expenses at $25.9 million in Q4 2025, $28.9 million in Q3 2025, and $27.9 million in Q2 2025.